All In Biotech

NDA 017426 · Padagis US

Desonide

Desonide · Topical · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Jun 8, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

Nov 1, 1974

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

4 Phase 3, 1 recruiting

FAERS reports

5,063

2,770 serious, 196 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 1, 2022.

INDICATIONS AND USAGE Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 1, 1974 Original approval · Type 3 - New Dosage Form
1 products under this application
  • DESONIDE · DESONIDE 0.05% · OINTMENT, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Desonide" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,209
  • macular degeneration787
  • off label use428
  • pain394
  • nausea381
  • pruritus361
  • rash339
  • headache327
  • erythema317
  • pyrexia307
  • psoriasis284
  • malaise283

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
200514
200621
200714
200824
200935
201027
201151
201275
2013110
2014113
2015216
2016277
2017248
2018296
2019279
2020341
2021619
2022508
2023579
2024405
2025460
2026342

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Desonide (Desonide)

2024 spending

$9.7M

Beneficiaries

119,821

176,861 claims

Per beneficiary

$81

$1.16 per unit

View as table
YearSpending
2020$23,953,741
2021$10,848,396
2022$11,016,654
2023$11,411,111
2024$9,734,412

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 41 on PubMed

Sponsor: Padagis US

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.